Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $8.30.

A number of research analysts have recently weighed in on the stock. Chardan Capital reissued a “buy” rating and set a $11.00 target price on shares of Cognition Therapeutics in a research report on Thursday, December 19th. B. Riley raised shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the company from $1.00 to $1.50 in a research report on Thursday, December 19th. Finally, HC Wainwright raised their price objective on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Thursday, December 19th.

Institutional Trading of Cognition Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Sigma Planning Corp lifted its stake in Cognition Therapeutics by 14.6% in the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after purchasing an additional 25,050 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its holdings in Cognition Therapeutics by 33.4% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after acquiring an additional 24,050 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Cognition Therapeutics during the 3rd quarter valued at about $27,000. Finally, SG Americas Securities LLC bought a new stake in shares of Cognition Therapeutics during the 4th quarter valued at about $26,000. 43.35% of the stock is currently owned by hedge funds and other institutional investors.

Cognition Therapeutics Stock Up 4.0 %

Cognition Therapeutics stock opened at $0.77 on Friday. Cognition Therapeutics has a twelve month low of $0.34 and a twelve month high of $2.95. The firm has a 50 day moving average price of $0.58 and a 200-day moving average price of $0.73. The company has a market capitalization of $31.96 million, a P/E ratio of -0.79 and a beta of 0.95.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.